General Motors Gains Speed Ahead Of Q3 Results As Deliveries Surge

General Motors Gains Speed Ahead Of Q3 Results As Deliveries Surge

General Motors previews earnings as EV strategy faces scrutiny; trucks shine while tariffs pressure margins, with factory upgrades supporting outlook. Latest Ratings for GM Date Firm Action From To Mar 2022 Benchmark Maintains Buy Feb 2022 Nomura Instinet Downgrades Buy Neutral Feb 2022 Morgan Stanley Downgrades Overweight Equal-Weight View More Analyst Ratings for GM View the Latest Analyst Ratings read more

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest. Latest Ratings for KZR Date Firm Action From To Dec 2021 Wells Fargo Initiates Coverage On Overweight Nov 2021 HC Wainwright & Co. Maintains Buy Jul 2021 JonesTrading Initiates Coverage On Buy View More Analyst Ratings for KZR View the Latest Analyst Ratings read more